Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire - Wed May 6, 10:00PM CDT

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common...

CYTK : 74.84 (-2.92%)
Cytokinetics: Q1 Earnings Snapshot AP - Tue May 5, 3:38PM CDT

Cytokinetics: Q1 Earnings Snapshot

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Proposed Public Offering of Common Stock GlobeNewswire - Tue May 5, 3:15PM CDT

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million...

CYTK : 74.84 (-2.92%)
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Tue May 5, 3:05PM CDT

U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ...

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy GlobeNewswire - Tue May 5, 6:30AM CDT

Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance  With Consistent Positive Findings Across Key Secondary Endpoints Company to Host Conference Call and Webcast Tuesday May...

CYTK : 74.84 (-2.92%)
Cytokinetics Reports Monday: The Market Has Already Priced In What Hasn't Been Delivered Barchart - Mon May 4, 4:08PM CDT

Barchart Research What to Expect from CYTK Earnings CYTK Generated May 4, 2026 Current Price $66.05 EPS Estimate $$-1.67 Consensus Rating Strong Buy Average Move 3.38% Cytokinetics Reports Monday: The...

CYTK : 74.84 (-2.92%)
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 GlobeNewswire - Mon May 4, 3:00PM CDT

Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced...

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress GlobeNewswire - Tue Apr 28, 6:30AM CDT

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress...

CYTK : 74.84 (-2.92%)
Cytokinetics to Announce First Quarter Results on May 5, 2026 GlobeNewswire - Tue Apr 21, 3:00PM CDT

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM...

CYTK : 74.84 (-2.92%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Mon Apr 20, 3:00PM CDT

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358...

CYTK : 74.84 (-2.92%)

Barchart Exclusives

Time to Buy: This Cheap High-Yield Dividend Stock Is Trading Near Multi-Year Lows Barchart - Wed May 6, 6:30PM CDT
Accenture's dividend yield is now over 3.6% thanks to the decline in its stock price. The stock's valuations have started to appear tempting at these levels, even though there are lingering concerns over AI being a risk to the company's business. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.